Evidence map›Paper›PMID 19663668›Full record

Trial reportPharmacogenomics2009

Predictors of poor response during asthma therapy differ with definition of outcome.

Angela J Rogers, Kelan G Tantisira, Anne L Fuhlbrigge, Augusto A Litonjua, Jessica A Lasky-Su, Stanley J Szefler, Robert C Strunk, Robert S Zeiger, Scott T Weiss

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Pharmacogenomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 56 citations in OpenAlex.

  1. FCER2 T2206C variant associated with FENO levels in asthmatic children using inhaled corticosteroids: The PACMAN study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019
    Trial
  2. Trial
  3. Patterns of inhaled corticosteroid use and asthma control in the Childhood Asthma Management Program Continuation Study.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2010
    Trial
  4. Review
  5. Article
  6. [The correlation between FCER2 gene polymorphism and the efficacy of inhaled corticosteroids in patients with chronic rhinosinusitis].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2023
    Article
  7. Article
  8. Article
  9. Genetic Determinants of Poor Response to Treatment in Severe Asthma.International journal of molecular sciences · 2021
    Review
  10. Article
  11. Pharmacogenetics of Pediatric Asthma: Current Perspectives.Pharmacogenomics and personalized medicine · 2020
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Genetic Signatures of Asthma Exacerbation.Allergy, asthma & immunology research · 2017
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Angela J RogersChanning Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. reajr@channing.harvard.edu
Kelan G Tantisira
Anne L Fuhlbrigge
Augusto A Litonjua
Jessica A Lasky-Su
Stanley J Szefler
Robert C Strunk
Robert S Zeiger
Scott T Weiss
Brigham and Women's Hospital · USHarvard University · USNational Jewish Health · USSt. Louis Children's Hospital · USUniversity of San Diego · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI KOSMISKI, LISA A. · 1985 to 2008
$52.6M
THE PHARMACOGENETICS OF ASTHMA TREATMENTU01HL065899 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G, WEISS, SCOTT T · 2000 to 2014
$38.5M
YOGA FOR THE MANAGEMENT OF HIV-METABOLIC SYNDROMESM01RR000036 · NCRR · WASHINGTON UNIVERSITY · PI NEWCOMER, JOHN W. · 1985 to 2007
$25.4M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · NCRR · JOHNS HOPKINS UNIVERSITY · PI EARLEY, CHRISTOPHER J · 1986 to 2007
$20.2M
SYSTEMS APPROACHES TO THE EPIDEMIOLOGY, GENETICS AND GENOMICS OF LUNG DISEASEST32HL007427 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI DAWN L DEMEO, Edwin K Silverman · 1985 to 2026
$13.6M
Molecular regulation of cytokine gene expressionP01HL067664 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KINET, JEAN-PIERRE M · 2001 to 2001
$2.0M
CLINICAL CENTER FOR CAMPN01HR016049 · HR · BRIGHAM AND WOMEN'S HOSPITAL · PI WEISS, SCOTT T · 1991 to 2000
$1.0M
CLINICAL COORDINATING CENTER FOR CAMPN01HR016044 · HR · JOHNS HOPKINS UNIVERSITY · PI TONASCIA, JAMES A · 1991 to 2006
$729k
Pharmacogenetic Linkage of Corticosteroid Response: Asthma Therapy ImplicationsK23HG003983 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G · 2006 to 2008
$485k
CLINICAL CENTER FOR CAMPN01HR016048 · HR · NATIONAL JEWISH HEALTH · PI SZEFLER, STANLEY J · 1991 to 2000
$0k
CLINICAL CENTER FOR CAMPN01HR016050 · HR · ASTHMA, INC. · PI SHAPIRO, GAIL G · 1991 to 2000
$0k
CLINICAL CENTER FOR CAMPN01HR016051 · HR · WASHINGTON UNIVERSITY · PI STRUNK, ROBERT C · 1991 to 2000
$0k
NCRR NIH HHS M01 RR000036NCRR NIH HHS M01 RR000051NCRR NIH HHS M01RR00051NCRR NIH HHS M01 RR002719NCRR NIH HHS M01RR0099718-24NCRR NIH HHS M01RR02719-14NCRR NIH HHS RR00036NHGRI NIH HHS K23 HG003983NHGRI NIH HHS K23 HG3983NHLBI NIH HHS N01 HR016044NHLBI NIH HHS N01-HR-16044NHLBI NIH HHS N01-HR-16045NHLBI NIH HHS N01-HR-16046NHLBI NIH HHS N01-HR-16047NHLBI NIH HHS N01-HR-16048NHLBI NIH HHS N01-HR-16049NHLBI NIH HHS N01-HR-16050NHLBI NIH HHS N01-HR-16051NHLBI NIH HHS N01-HR-16052NHLBI NIH HHS P01 HL067664NHLBI NIH HHS P01 HL67664NHLBI NIH HHS T32 HL007427NHLBI NIH HHS T32 HL07427NHLBI NIH HHS U01 HL065899NHLBI NIH HHS U01 HL65899
6 · The paper itself

Abstract

aimsTo evaluate phenotypic and genetic variables associated with a poor long-term response to inhaled corticosteroid therapy for asthma, based independently on lung function changes or asthma exacerbations. MATERIALS &

methodsWe tested 17 phenotypic variables and polymorphisms in FCER2 and CRHR1 in 311 children (aged 5-12 years) randomized to a 4-year course of inhaled corticosteroid during the Childhood Asthma Management Program (CAMP).

resultsPredictors of recurrent asthma exacerbations are distinct from predictors of poor lung function response. A history of prior asthma exacerbations, younger age and a higher IgE level (p < 0.05) are associated with recurrent exacerbations. By contrast, lower bronchodilator response to albuterol and the minor alleles of RS242941 in CRHR1 and T2206C in FCER2 (p < 0.05) are associated with poor lung function response. Poor lung function response does not increase the risk of exacerbations and vice versa (p = 0.72).

conclusionGenetic and phenotypic predictors of a poor long-term response to inhaled corticosteroids differ markedly depending on definition of outcome (based on exacerbations vs lung function). These findings are important in comparing outcomes of clinical trials and in designing future pharmacogenetic studies.

Indexed as

Treatment OutcomeAdministration, InhalationAdrenal Cortex HormonesAsthmaChildChild, PreschoolCRF Receptor, Type 1FemaleFollow-Up StudiesGenotypeHumansLectins, C-TypeMalePhenotypePredictive Value of TestsReceptors, Corticotropin-Releasing HormoneAdrenal Cortex HormonesCRF Receptor, Type 1FCER2 protein, humanLectins, C-TypeReceptors, Corticotropin-Releasing HormoneReceptors, IgE

Identifiers

PMID19663668
PMCPMC2746392
OpenAlexW2103596301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.